Abstract
Tumor-infiltrating lymphocytes (TIL) are an important component of the tumor environment. Their role in tumor growth and progression has been debated for decades, with the current emphasis on survival benefits TIL appear to bestow on the host when present in situ as large aggregates of activated T and B cells. Gene signatures and protein profiling of TIL provide clues about their potential functions in the tumor, and correlations with clinicopathological tumor characteristics, clinical outcome, and patients’ survival data indicate that TIL exert influence on the disease progression, especially in colorectal carcinomas and breast cancer. At the same time, the recognition that TIL signatures vary in composition and with time, and that TIL interactions with the tumor cells are complex, calls for a more careful assessment of their prognostic significance. The mechanisms tumors utilize to subvert the host immune system are well-known. The balance between pro- and anti-tumor responses of TIL might be orchestrated by the tumor serving as a measure of its aggressiveness and potentially providing a key to selecting therapeutic strategies and to prognosis.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- Ab:
-
Antibody
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- CFC:
-
Cytokine flow cytometry
- CRC:
-
Colorectal cancer
- CTL:
-
Cytolytic T cell
- CTLA-4:
-
Cytotoxic T lymphocyte-associated antigen-4
- DC:
-
Dendritic cells
- ER:
-
Estrogen receptor
- IGKC:
-
IgG kappa chain
- MDSC:
-
Myeloid-derived suppressor cells
- MHC:
-
Major histocompatibility complex
- NK:
-
Natural killer cells
- NSCLC:
-
Non-small cell lung cancer
- PD-1:
-
Programmed cell death protein-1
- PGE2:
-
Prostaglandin E2
- PMN:
-
Polymorphonuclear neutrophils
- TA:
-
Tumor-associated antigen
- TCR:
-
T-cell receptor
- TGF-β:
-
Transforming growth factor-β
- Th cell:
-
T helper cell
- TIL:
-
Tumor-infiltrating lymphocytes
- TMA:
-
Tissue microarrays
- Treg:
-
Regulatory T cells
- VEGF:
-
Vascular endothelial growth factor
References
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18(1):11–18
Fregni G et al (2012) NK cells sense tumors, course of disease and treatments: consequences for NK-based therapies. Oncoimmunology 1(1):38–47
Schmidt M et al (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18(9):2695–2703
Nielsen JS et al (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281–3292
Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–469
von Kleist S et al (1987) Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int J Cancer 40(1):18–23
Martinet L et al (2011) Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 71(17):5678–5687
Chew V et al (2012) Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61(3):427–438
Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964
Fridman WH et al (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71(17):5601–5605
Pages F et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666
Mlecnik B et al (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618
Sato E et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538–18543
Mahmoud SM et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955
Galon J et al (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1
Britten CM et al (2011) Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 60(1):15–22
Albers AE et al (2005) Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 54(11):1072–1081
Kim JW et al (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11(3):1010–1020
Hoffmann TK et al (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8(8):2553–2562
Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41(1):245–251
Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45):5904–5912
Ferrone S, Whiteside TL (2007) Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16(4):755–774, viii
Mittendorf EA, Sharma P (2010) Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines 9(1):89–105
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264
Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22(4):327–334
Marigo I et al (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162–179
Romagnani S (1997) The Th1/Th2 paradigm. Immunol Today 18(6):263–266
Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54(8):721–728
Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188(12):2199–2204
Tatsumi T et al (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196(5):619–628
Teschendorff AE et al (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8(8):R157
Teschendorff AE et al (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 10:604
Yang L et al (2012) Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys 62(1):153–159
Kryczek I et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6):1141–1149
Silva-Santos B (2010) Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol 40(7):1873–1876
Lanca T, Silva-Santos B (2012) The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology 1(5):717–725
Whiteside TL, Schuler P, Schilling B (2012) Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12(10):1383–1397
Schmidt M et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405–5413
Whiteside TL, Ferrone S (2012) For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res 18(9):2417–2419
Biragyn A, Lee-Chang C (2012) A new paradigm for an old story: the role of regulatory B cells in cancer. Front Immunol 3:206
Saze Z et al (2013) Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122(1):9–18
Vivier E et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44–49
Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7(5):329–339
Platonova S et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422
Schantz SP et al (1986) Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 77(4):869–875
Liu S et al (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14(2):R48
Fridman WH et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Wien
About this chapter
Cite this chapter
Whiteside, T.L. (2014). Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. In: Klink, M. (eds) Interaction of Immune and Cancer Cells. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1300-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1300-4_6
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1299-1
Online ISBN: 978-3-7091-1300-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)